Its mRNA levels in castration resistant prostate cancer with bone metastatic samples were significantly lower than those without metastasis [10], indicating that HSD17B6 dysfunction involved in prostate cancer metastases. This evidence concerns the gene HSD17B6 and prostate cancer.